MRNA climbs nearly 3% after strong Phase 3 cancer vaccine data and bullish technical signals

Traders Union
All News
Stocks
Moderna rises 2.73% today on data

Highlights

Moderna reports positive Phase 3 results for its intismeran mRNA vaccine in high-risk melanoma patients, developed with Merck.
Quarterly earnings for Q3 2026 are projected to show lower revenue and a year-over-year loss, with shifts in major institutional positions.
Shares of Moderna trade in a bullish structure, with strong upward momentum and an expected five-day range of $214.66 to $243.11.

Investor rotation intensifies amid earnings outlook, fund flows, and new deals

Moderna has gained investor attention after reporting positive Phase 3 trial results for intismeran, its personalized mRNA cancer vaccine developed with Merck, in high-risk melanoma patients. The company is also set to release third-quarter 2026 earnings before the market opens on November 6, with consensus estimates projecting lower revenue and a quarterly loss year-over-year. Recent institutional activity includes BOCHK Asset Management Ltd acquiring a new stake and Bank Julius Baer & Co. Ltd Zurich significantly reducing its holdings, alongside an extended collaboration with Personalis in clinical development programs.

Anton Kharitonov, expert at Traders Union, sees optimism around Moderna's recent gains but urges caution. He notes that while the technical structure is bullish, upcoming earnings are expected to show weaker fundamentals and potential revenue loss. The mixed institutional flows highlight lingering doubts about the stock's long-term prospects. Kharitonov warns that volatility remains high, especially with resistance at $228.27 limiting upside. "Despite the short-term enthusiasm, I believe investors should remain wary of downside risks if support at $222.01 fails," he states.

Viktoras Karapetjanc, expert at Traders Union, emphasizes the market's constructive response to Moderna's positive Phase 3 vaccine results and strong institutional engagement. He believes the bullish technical setup and momentum above major moving averages signal further growth opportunities in the coming sessions. Karapetjanc highlights that extended clinical collaborations and active corporate moves support the upward narrative. He notes confidence remains high as the stock trades near resistance, anticipating market setups for a breakout. "With the bullish structure intact, I expect upside beyond $228.27 is well within reach," says Karapetjanc.

Parshwa Turakhiya, analyst, observes sentiment-driven momentum fueling Moderna's price action after the latest news. He sees short-term opportunities developing between $222.01 and $243.11 as volatility drives trading setups. Turakhiya suggests that neutral readings on relative strength and key oscillators favor active tactical positioning rather than directional bets. "In this rangebound environment, I advise traders to focus on quick entries and exits as the market tests support and resistance," he recommends.

Bullish alignment holds above key supports as momentum signals strengthen

Moderna is trading above its 20-day, 50-day, and 200-day moving averages at $226.85, with the respective averages at $215.44, $183.79, and $87.43. This positions the stock in a bullish structure across short-, medium-, and long-term trends, further reinforced by the MA-50 versus MA-200 alignment and continued upside momentum. The closest support is at $222.01, and resistance is at $228.27. Momentum indicators, including the MACD and Average Directional Index (ADX), show buy signals, while the RSI, Stochastic RSI, and Commodity Channel Index (CCI) remain neutral. Positive Bull/Bear Power (BBP) and a strong Awesome Oscillator support ongoing strength, as the stock maintains mid-session range with intraday volatility at 5.95%.

Previously it was reported that Moderna maintained a bullish technical setup following positive Phase 3 data for its melanoma vaccine, with analysts highlighting ongoing momentum. Now, with institutional positioning shifting and near-term resistance tightening, traders should monitor for a decisive move above $228.27 or below $222.01 as indicators for the next directional breakout.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.